Immunohistochemical analysis of 147 cases of low-grade endometrial stromal sarcoma: refining the immunohistochemical profile of LG-ESS on a large, molecularly confirmed series

Varování

Publikace nespadá pod Ústav výpočetní techniky, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.

Autoři	FLIDROVA Miroslava DUNDR Pavel VRANKOVA Romana NEMEJCOVA Kristyna CIBULA David PONCOVA Renata MICHALOVA Kvetoslava BOUDA Jiri LACO Jan NDUKWE Munachiso RYS Janusz KSIAZEK Mariusz BERJON Alberto ZAPARDIEL Ignacio FRANIN Ivan NJAVRO Antonela HAUSNEROVÁ Jitka BRETOVÁ Petra ZIDLIK Vladimir KLAT Jaroslav KRASZNAI Zoard Tibor POKA Robert VOLODKO Nataliya YEZHOVA Iryna PILKA Radovan MAREK Radim KOLNIKOVA Georgina KRKOSKA Milan HALASKA Michael DROZENOVA Jana DOLINSKA Dagmar KALIST Vladimir BOBINSKI Marcin OSTROWSKA-LESKO Marta BIZON Magdalena SAWICKI Wlodzimierz STUKAN Maciej GRABOWSKA Karolina JEDRYKA Marcin POPRAWSKI Tymoteusz STOLNICU Simona CAPILNA Mihai Emil SPURKOVA Zuzana ZIKAN Michal CICCARONE Francesca SCAMBIA Giovanni SHARASHENIDZE Archil GUDADZE Miranda PIATNYTSKA Tetiana VARCHAK Ihor KENDALL BARTU Michaela
Rok publikování	2025
Druh	Článek v odborném periodiku
Časopis / Zdroj	Virchows Archiv
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://link.springer.com/article/10.1007/s00428-025-04026-4
Doi	http://dx.doi.org/10.1007/s00428-025-04026-4
Klíčová slova	Low-grade endometrial stromal sarcoma; LG-ESS; Immunohistochemistry; Endometrial stromal markers; Smoothelin
Popis	Low-grade endometrial stromal sarcoma (LG-ESS) can present diagnostic challenges, due to its overlapping morphological features with other uterine mesenchymal tumors. Misdiagnosis rates remain significant, and immunohistochemical data for LG-ESS are limited to small series and inconsistent antibody panels. This study aimed to refine the IHC profile of LG-ESS by analyzing a large, molecularly confirmed series of 147 cases using a panel of 24 antibodies, including newer markers like transgelin and smoothelin. CD10 and IFITM1, key endometrial stromal markers, were expressed in 86% (92% of those extensively) and 69% (60% of those extensively) of cases, with fusion-positive tumors showing significantly higher expression. Smooth muscle markers (alpha-SMA, desmin, h-caldesmon, calponin, transgelin) were variably expressed, predominantly in focal or low-intensity patterns, with alpha-SMA reaching the highest frequency of expression (44%). However, the intensity of smooth muscle marker expression was usually very low. Smoothelin was rarely expressed. Hormone receptors were frequently positive, with PR showing a higher frequency (92% vs. 83%) and intensity than ER. Markers like S-100, HMB45, and CD117 were largely negative; all tumors were p53 wild-type, with preserved SMARCB1/SMARCA4 expression and ALK and ROS1 negativity. This work represents the largest molecularly validated IHC study on LG-ESS, providing a robust diagnostic profile for routine pathology. By addressing key diagnostic limitations and examining newer markers, our study supports a more standardized approach to diagnosing LG-ESS and underscores the value of immunohistochemical panels, particularly in fusion-negative tumors where diagnosis relies on morphological and immunohistochemical interpretation. These findings contribute critical data for improving diagnostic accuracy.
Související projekty:	BBMRI.cz - Síť českých biobank